The Committee on Drugs (COD) reviews all aspects of pediatric pharmacology including drug indications, contraindications, absorption rates, routes of administration, dosing, use precautions and mode of action as they apply to children. COD also advises the Board of Directors in matters related to drug labeling, safety and efficacy for both prescription and over-the-counter drugs; monitors federal legislation related to the drug approval process and promotes the need for expanded pediatric drug trials.

View policy statements

Committee Members

J Routt Reigart, MD, FAAP
Mount Pleasant, SC

Adam D Adler, MD, FAAP
Houston TX

Olive S. Eckstein, MD, FAAP
Houston TX

Jennifer L. Goldman, MD, MS, FAAP
Kansas City, MO

Diane E Hindman, MD, FAAP
Mesa, AZ

Philip A Verhoef, MD, FAAP
Honolulu, HI

Kevin M Watt MD, PhD, FAAP 
Salt Lake City, UT

John James Alexander, MD, FAAP
Food and Drug Administration

Perdita Taylor-Zapata, MD
National Institutes of Health

Robyn P. Thom, MD
American Academy of Child and Adolescent Psychiatry

Kate Woodworth, MD
Centers for Diseases Control and Prevention

Geert W 't Jong MD, PhD
Canadian Paediatric Society

Contact COD